Successful, we will reply to you quickly.OK
Please select the quantity.OK
Your message is being sent, please wait.Close
Send mail failed, please send again!Close
Products are for research use only. Not for human use. We do not sell to patients.
Paclitaxel Chemical Structure
|Product name: Paclitaxel|
|Cat. No.: HY-B0015|
Paclitaxel is a microtubule polymer stabilizer with IC50 of 0.1 pM in human endothelial cells.
IC50 Value: 0.1 pM
in vitro: Paclitaxel inhibits non-endothelial type human cells at 104 - to 105 -fold higher concentrations, with IC50 of 1 nM-10 nM. The selectivity of Paclitaxel inhibition of cell proliferation is also species specific, as mouse ECs are not sensitive to Paclitaxel at ultra low concentrations. Inhibition of human ECs by Paclitaxel at ultra low concentrations does not affect the cellular microtubule structure, and the treated cells do not show G2/M cell cycle arrest and apoptosis, suggesting a novel but as yet unidentified mechanism of action. In an in vitro angiogenesis assay, Paclitaxel at ultra low concentrations blocks human ECs from forming sprouts and tubes in the three-dimensional fibrin matrix. In the presence of SMF, the efficient concentration of Paclitaxel on K562 cells is decreased from 50 to 10 ng/mL. The cell cycle arrest effect of Paclitaxel with or without SMF on K562 cells is correlated with DNA damage. Paclitaxel alone causes a time-dependent inhibition of CDK1 in four cell lines including A549 cells, H358, H1395 cells and H1666 cells.
in vivo: The inhibition rations of Paclitaxel alone on BC-V and BC-ER tumors are 49.78% and 51.23%, respectively. Treatment of six cycles of 20 mg/kg Paclitaxel significantly reduces the percentages of Ki-67-positive cells to 20.4% in BC-V tumors and 25.1% in BC-ER tumors, respectively.
|M.Wt||853.91||Storage||Please store the product under the recommended conditions in the Certificate of Analysis.|
|Solvent & Solubility||
DMSO: ≥ 36 mg/mL
|1 mg||5 mg||10 mg|
|1 mM||1.1711 mL||5.8554 mL||11.7108 mL|
|5 mM||0.2342 mL||1.1711 mL||2.3422 mL|
|10 mM||0.1171 mL||0.5855 mL||1.1711 mL|
|Product Name||Sponsor Only||Condition||Start Date||End Date||Phase||Last Change Date|
|Paclitaxel||Aarhus University Hospital||Angina||31-AUG-04||31-JAN-09||Phase 4||31-JUL-13|
|Taipei-Veterans General Hospital||Metastatic lung cancer||30-APR-08||01-OCT-09||Phase 4||28-OCT-13|
|Roche Holding AG||Metastatic breast cancer||31-MAR-10||31-JAN-15||Phase 4||06-NOV-13|
|Eurocor GmbH||Restenosis||28-FEB-10||01-MAR-11||Phase 4||20-SEP-13|
|Roche Holding AG||Breast tumor||31-OCT-10||31-DEC-12||Phase 4||06-NOV-13|
. Weber B, Largillier R, Ray-Coquard I, et al. A potentially neuroprotective role for erythropoietin with paclitaxel treatment in ovarian cancer patients: a prospective phase II GINECO trial. Support Care Cancer. 2013 Feb 19.
. Pan Z, Gollahon L. Paclitaxel attenuates Bcl-2 resistance to apoptosis in breast cancer cells through an endoplasmic reticulum-mediated calciumrelease in a dosage dependent manner. Biochem Biophys Res Commun. 2013 Feb 13. pii: S0006-291X(13)00259-3.
. Habib S, Delourme J, Dhalluin X, et al. Bevacizumab and weekly paclitaxel for non-squamous non small cell lung cancer patients: A retrospective study. Lung Cancer. 2013 Feb 13. pii: S0169-5002(13)00025-1.
. Rao S, He L, Chakravarty S, et al. Characterization of the Taxol binding site on the microtubule. Identification of Arg(282) in beta-tubulin as the site of photoincorporation of a 7-benzophenone analogue of Taxol. J Biol Chem. 1999 Dec 31;274(53):37990-4.
10-Deacetyl-7-xylosyl paclitaxel is a Paclitaxel derivative with improved pharmacological features and higher water solubility.
10-Oxo Docetaxel(Docetaxel Impurity) is a novel taxoid having remarkable anti-tumor properties and a Docetaxel intermediate.
2-methoxyestradiol (2ME2; NSC-659853) is a natural metabolite of estrogen that is known to inhibit HIF-1 alpha with an IC50 of 0.71 (plusmn) 0.11 (mu)M for the inhibition of BPAEC migration.
4(acute)-Demethylepipodophyllotoxin(4(acute)-DMEP) is a key intermediate compound for the preparation of podophyllotoxin-type anti-cancer drugs; a potent inhibitor of microtubule assembly.
7-Epi-10-oxo-docetaxel (Docetaxel Impurity D) is a impurity of docetaxel detected by high performance liquid chromatography (HPLC).
7-Epi-10-oxo-docetaxel (Docetaxel Impurity C; 7-Epitaxotere) is a impurity of docetaxel.
7-xylosyltaxol(Taxol-7-xyloside) is a taxol (Paclitaxel) derivative; Paclitaxel binds to tubulin and inhibits the disassembly of microtubules.
ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 (mu)M in neuroblastoma and non-neuroblastoma cell lines, respectively.
alpha-Amanitin is a potent inhibitor of DNA-dependent RNA polymerase II.
Auristatin E is a cytotoxic tubulin modifier with potent and selective antitumor activity; MMAE analog and cytotoxin in Antibody-drug conjugates.